RET and medullary thyroid gland carcinoma: In parallel, data from the LIBRETTO-531 Phase III study (NCT04211337), evaluating selpercatinib versus physician’s choice of the MKIs cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic RET-mutant MTC, have been published [21].